Your browser doesn't support javascript.
loading
The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades.
Mendez, Joe S; Ostrom, Quinn T; Gittleman, Haley; Kruchko, Carol; DeAngelis, Lisa M; Barnholtz-Sloan, Jill S; Grommes, Christian.
Afiliação
  • Mendez JS; Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Ostrom QT; Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio.
  • Gittleman H; Central Brain Tumor Registry of the United States, Hinsdale, Illinois.
  • Kruchko C; Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio.
  • DeAngelis LM; Central Brain Tumor Registry of the United States, Hinsdale, Illinois.
  • Barnholtz-Sloan JS; Central Brain Tumor Registry of the United States, Hinsdale, Illinois.
  • Grommes C; Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York.
Neuro Oncol ; 20(5): 687-694, 2018 04 09.
Article em En | MEDLINE | ID: mdl-29036697
ABSTRACT

Background:

There has been significant improvement in treatment outcomes of primary central nervous system lymphoma (PCNSL) at specialized centers over the past several decades; however, it is unclear if these changes have translated to benefits in the general population.

Methods:

In this study, we utilized 2 national databases to examine survival trends over time for PCNSL the Central Brain Tumor Registry of the United States (CBTRUS, 2000-2013) and 18 registries from the Surveillance, Epidemiology, and End Results program (SEER, 1973-2013).

Results:

The annual incidence of PCNSL in 2013 was 0.4 per 100000 population (CBTRUS/SEER). Incidence increased from 0.1 per 100000 in the 1970s to 0.4 per 100000 in the 1980s, correlating with an increase in the diagnosis of patients ≥70 years (1973 0.2 vs 2013 2.1 [SEER]). Incidence rates differed greatly between young and elderly patients (age 20-29 y 0.08 vs 70-79 y 4.32 [CBTRUS]). Even though the median overall survival of all patients doubled from 12.5 months in the 1970s to 26 months in the 2010s, this survival benefit was limited to patients <70 years. Survival in the elderly population has not changed in the last 40 years (6 mo in the 1970s vs 7 mo in the 2010s, P = 0.1).

Conclusion:

The poor outcome seen in the particularly vulnerable elderly patient population highlights the need for clinical trials targeting the elderly in hopes of improving treatment strategies and survival.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Mortalidade / Neoplasias do Sistema Nervoso Central / Linfoma Tipo de estudo: Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Aged80 / Child / Child, preschool / Female / Humans / Infant / Male País/Região como assunto: America do norte Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Mortalidade / Neoplasias do Sistema Nervoso Central / Linfoma Tipo de estudo: Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Aged80 / Child / Child, preschool / Female / Humans / Infant / Male País/Região como assunto: America do norte Idioma: En Ano de publicação: 2018 Tipo de documento: Article